{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:00:42Z","timestamp":1790341242246,"version":"4.1.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The renaming of non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD), and subsequently to metabolic dysfunction-associated steatotic liver disease (MASLD), signals a paradigm shift that repositions hepatic steatosis as a systemic metabolic disorder rather than a diagnosis by exclusion. This review synthesizes the evidence supporting the nomenclature transition, examines the pathogenic mechanisms driving disease progression, evaluates the clinical implications of the lean MAFLD phenotype, and surveys the evolving therapeutic landscape. Oxidative stress, chronic low-grade inflammation, and mitochondrial dysfunction form an interconnected network propelling the trajectory from simple steatosis to steatohepatitis and fibrosis. The bidirectional liver\u2013adipose tissue communication axis, modulated by micronutrient homeostasis, has emerged as an integrative framework for understanding disease pathobiology. Lean MAFLD, present in 20\u201340% of affected individuals despite normal body mass index, challenges obesity-centered screening approaches and underscores the necessity of metabolic phenotyping in routine clinical practice. Extrahepatic complications\u2014particularly subclinical cardiovascular injury, type 2 diabetes-associated hepatocellular carcinoma, and cardiomyopathy\u2014remain the principal causes of death in this population. The regulatory approval of resmetirom in March 2024, together with promising phase II data on incretin-based therapies, FGF21 analogs, and PPAR modulators, has begun to reshape a therapeutic field that had long relied on lifestyle modification alone. We also discuss the gut\u2013liver axis, genetic predisposition, economic burden, and multidisciplinary management models that together define the contemporary understanding of this disease. This review integrates these developments and identifies key gaps warranting further investigation.<\/jats:p>","DOI":"10.3389\/fendo.2026.1950107","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:16:07Z","timestamp":1790338567000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic dysfunction-associated fatty liver disease: redefining the conceptual framework from nomenclature to emerging therapeutic paradigms"],"prefix":"10.3389","volume":"17","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[{"name":"Department of General Surgery, Affiliated Yongkang First People\u2019s Hospital of Hangzhou Medical College","place":["Yongkang, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of non-alcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.01.026","article-title":"Healthcare and socioeconomic costs of NAFLD: a global framework to navigate the uncertainties","volume":"79","author":"Allen","year":"2023","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.14744\/hf.2020.2020.0024","article-title":"Metabolic-associated fatty liver disease: time to integrate ground-breaking new terminology to our clinical practice","volume":"1","author":"Demirtas","year":"2020","journal-title":"Hepatol Forum"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2023.05.001","article-title":"MAFLD is the optimal definition, and MASLD is the optimal terminology","volume":"18","author":"Yilmaz","year":"2023","journal-title":"Clin Liver Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.01.027","article-title":"Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD","volume":"19","author":"Henry","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416226","article-title":"Fatty liver disease\u2014alcoholic and non-alcoholic: similar but different","volume":"23","author":"Malnick","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2024.00311","article-title":"Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5009\/gnl250444","article-title":"The chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease paradox: friend or foe","volume":"20","author":"Huang","year":"2026","journal-title":"Gut Liver"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert panel statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000670","article-title":"Metabolic dysfunction-associated steatotic liver disease: update and impact of new nomenclature on AASLD practice guidance","volume":"79","author":"Kanwal","year":"2024","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.04.013","article-title":"Metabolic dysfunction-associated steatotic liver disease: evolution of the final terminology","volume":"124","author":"Portincasa","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg","year":"2026","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2025.2492767","article-title":"MAFLD vs. MASLD: a year in review","volume":"20","author":"Jiang","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.02.002","article-title":"MAFLD: Now is the time to capitalize on the momentum","volume":"74","author":"Eslam","year":"2021","journal-title":"J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101066","article-title":"The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease","volume":"6","author":"Younossi","year":"2024","journal-title":"JHEP Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.114.303741","article-title":"Adipocyte dysfunction, inflammation and metabolic comorbidities\u2014potential role of phagocytic activity and cytokine secretion","volume":"34","author":"Kloting","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2016.05.004","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23472","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ph17101354","article-title":"Metabolic-associated fatty liver disease: the influence of oxidative stress, inflammation, mitochondrial dysfunctions, and the role of polyphenols","volume":"17","author":"Tauil","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00013.2008","article-title":"Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.08.006","article-title":"MAFLD: a ferroptotic disease","volume":"32","author":"Cui","year":"2026","journal-title":"Trends Mol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13060731","article-title":"Oxidative stress as a target for non-pharmacological intervention in MAFLD: could there be a role for EVOO","volume":"13","author":"Seidita","year":"2024","journal-title":"Antioxidants"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-018-0011-z","article-title":"The gut\u2013liver axis and the intersection with the microbiome","volume":"15","author":"Tripathi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized controlled clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.08.002","article-title":"Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome modulation","volume":"35","author":"Ni","year":"2023","journal-title":"Cell Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0811","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Tilg","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and therapeutic implications","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cells13191631","article-title":"The interplay between liver and adipose tissue in the onset of liver diseases: exploring the role of vitamin deficiency","volume":"13","author":"Tattoli","year":"2024","journal-title":"Cells"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-85","article-title":"Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes","volume":"9","author":"Barchetta","year":"2011","journal-title":"BMC Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1039\/d0fo01095b","article-title":"Vitamin D and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Guo","year":"2020","journal-title":"Food Funct"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094901","article-title":"Vitamin D and metabolic dysfunction-associated steatotic liver disease (MASLD): novel mechanistic insights","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.042","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Passi","year":"2020","journal-title":"Gastroenterology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1399517","article-title":"Association between thyroid function and nonalcoholic fatty liver disease: a dose-response meta-analysis","volume":"15","author":"Xiang","year":"2024","journal-title":"Front Endocrinol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332491","article-title":"Association between primary hypothyroidism and metabolic dysfunction-associated steatotic liver disease: a Mendelian randomization study","volume":"73","author":"Mantovani","year":"2024","journal-title":"Gut"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatotic liver disease","volume":"82","author":"Ratziu","year":"2025","journal-title":"J Hepatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-28232-x","article-title":"Impact of thyroid dysfunction and diabetes on fibrosis and steatosis stages in metabolic dysfunction-associated steatotic liver disease","volume":"15","author":"Saleh","year":"2025","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26263","article-title":"Carriage of the PNPLA3 rs738409 C>G polymorphism confers susceptibility to nonalcoholic fatty liver disease","volume":"57","author":"Grebely","year":"2013","journal-title":"Hepatology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101485","article-title":"Genome-wide meta-analysis identifies nine loci associated with higher risk of hepatocellular carcinoma development","volume":"7","author":"Ghouse","year":"2025","journal-title":"JHEP Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/20420188241252543","article-title":"MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight","volume":"15","author":"Pan","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00635-5","article-title":"Metabolic (dysfunction)-associated fatty liver disease in individuals with a lean phenotype","volume":"19","author":"Eslam","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02373-1","article-title":"Risk factor analysis and predictive model construction of lean MAFLD: a cross-sectional study of a hospital population in China","volume":"30","author":"Zhu","year":"2025","journal-title":"Eur J Med Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336127","article-title":"Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts","volume":"75","author":"Huo","year":"2026","journal-title":"Gut"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32340","article-title":"Association between lean non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"76","author":"Cinnamon","year":"2022","journal-title":"Hepatology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114521002270","article-title":"Effect of Mediterranean diet on liver enzymes: a systematic review and meta-analysis of randomised controlled trials","volume":"128","author":"Sangouni","year":"2022","journal-title":"Br J Nutr"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105110","article-title":"Sedentary lifestyle, physical activity, and gastrointestinal diseases: evidence from Mendelian randomization and observational analyses","volume":"103","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000417","article-title":"Sleep duration, sleep quality, and the development of nonalcoholic fatty liver disease: a cohort study","volume":"12","author":"Um","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107251","article-title":"The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: a meta-analysis","volume":"204","author":"Pan","year":"2024","journal-title":"Pharmacol Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70793","article-title":"Environmental endocrine-disrupting chemicals and metabolic dysfunction-associated steatotic liver disease: mechanisms and evidence","volume":"46","author":"Zhao","year":"2026","journal-title":"Liver Int"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100912","article-title":"Long-term exposure to ambient PM2.5 and its constituents is associated with MAFLD","volume":"5","author":"Guo","year":"2023","journal-title":"JHEP Rep"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaf101","article-title":"Long-term exposure to ambient air pollution and the incidence of nonalcoholic fatty liver disease: a prospective cohort study","volume":"54","author":"Chen","year":"2025","journal-title":"Int J Epidemiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14943","article-title":"Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"41","author":"Burra","year":"2021","journal-title":"Liver Int"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-025-01833-0","article-title":"Sex and gender differences in metabolic dysfunction-associated liver disease","volume":"45","author":"Penmetsa","year":"2026","journal-title":"Indian J Gastroenterol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab658","article-title":"Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome","volume":"107","author":"Falzarano","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02775-0","article-title":"The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome","volume":"21","author":"Liu","year":"2023","journal-title":"BMC Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0249","article-title":"Diabetes mellitus and increased risk of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"181","author":"Kluge","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s274933","article-title":"Mechanisms underlying hepatocellular carcinoma progression in patients with type 2 diabetes","volume":"10","author":"Shi","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32197","article-title":"Trends in the burden of nonalcoholic fatty liver disease in the United States","volume":"75","author":"Kwan","year":"2022","journal-title":"Hepatology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i23.107100","article-title":"Hepatocellular carcinoma in patients without cirrhosis","volume":"31","author":"Sato-Espinoza","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101781","article-title":"Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus","volume":"46","author":"Li","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2024.06.031","article-title":"Modifiable risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease","volume":"137","author":"Xiao","year":"2024","journal-title":"Am J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.07.030","article-title":"Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery calcium score and traditional risk factors","volume":"19","author":"Meyersohn","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164946","article-title":"Association between atherogenic dyslipidemia and subclinical myocardial injury in the general population","volume":"13","author":"Elbadawi","year":"2024","journal-title":"J Clin Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06981-w","article-title":"Plasma SHBG levels as an early predictor of response to bariatric surgery","volume":"34","author":"Gabriel-Medina","year":"2024","journal-title":"Obes Surg"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70747","article-title":"Global prevalence, incidence, and outcomes of coexisting MASLD and chronic kidney disease: a meta-analysis","volume":"46","author":"Kueh","year":"2026","journal-title":"Liver Int"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.14744\/hf.2023.2023.0011","article-title":"TASL practice guidance on the clinical assessment and management of patients with nonalcoholic fatty liver disease","volume":"4","author":"Yilmaz","year":"2023","journal-title":"Hepatol Forum"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice","year":"2018","journal-title":"Clin Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1421386","article-title":"Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease","volume":"11","author":"Chen","year":"2025","journal-title":"Front Nutr"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27670","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis","volume":"61","author":"Kayadibi","year":"2015","journal-title":"Hepatology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2026.03.021","article-title":"Quantitative regression of qFibrosis with resmetirom: exploratory histologic endpoints from the MAESTRO-NASH program","volume":"85","author":"Schattenberg","year":"2026","journal-title":"J Hepatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates and future directions","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2546812","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives","volume":"34","author":"Fiorucci","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized, double-blind, placebo-controlled phase 2 trial","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3278","article-title":"Efficacy and safety of fibroblast growth factor-21 analogs for the treatment of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"116","author":"Jeong","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with MASH: NATIVE trial results","volume":"83","author":"Barb","year":"2025","journal-title":"J Hepatol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1789019","article-title":"Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives","volume":"17","author":"Tamehri Zadeh","year":"2026","journal-title":"Front Pharmacol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.02.035","article-title":"Target populations for novel triglyceride-lowering therapies","volume":"85","author":"Nordestgaard","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2541035","article-title":"Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a pilot study","volume":"17","author":"Groenewegen","year":"2025","journal-title":"Gut Microbes"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1950107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:16:09Z","timestamp":1790338569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1950107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":95,"alternative-id":["10.3389\/fendo.2026.1950107"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1950107","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1950107"}}